AEON Biopharma Inc (AMEX:AEON) price on Thursday, March 20, fall -3.33% below its previous day’s close as a downside momentum from buyers pushed the stock’s value to $0.73.
A look at the stock’s price movement, the close in the last trading session was $0.75, moving within a range at $0.6701 and $0.8698. The beta value (5-Year monthly) was 0.257. Turning to its 52-week performance, $1069.20 and $0.40 were the 52-week high and 52-week low respectively. Overall, AEON moved -90.76% over the past month.
AEON Biopharma Inc’s market cap currently stands at around $0.81 million, with investors looking forward to this quarter’s earnings report slated for on 2024-Nov-12.
Turning to the stock’s technical picture we see that short term indicators suggest on average that AEON is a 100% Sell. On the other hand, the stock is on average a 100% Sell as suggested by medium term indicators while long term indicators are putting the stock in 100% Sell category.
1 analyst(s) have given their forecast ratings for the stock on a scale of 1.00-5.00 for a strong buy to strong sell recommendation. A total of 0 analyst(s) rate the stock as a Hold, 1 recommend AEON as a Buy and 0 give it an Overweight rating. Meanwhile, 0 analyst(s) rate the stock as Underweight and 0 say it is a Sell. As such, the average rating for the stock is Buy which could provide an opportunity for investors keen on increasing their holdings of the company’s stock.
AEON’s current price about -56.96% and -89.18% off the 20-day and 50-day simple moving averages respectively. The Relative Strength Index (RSI, 14) currently prints 24.53, while 7-day volatility ratio is 19.64% and 32.11% in the 30-day chart. Further, AEON Biopharma Inc (AEON) has a beta value of 0.21, and an average true range (ATR) of 0.80.
If we refocus on AEON Biopharma Inc (AMEX:AEON), historical trading data shows that trading volumes averaged 8.82 over the past 10 days and 3.36 million over the past 3 months. The company’s latest data on shares outstanding shows there are 1.11 million shares.
The 31.68% of AEON Biopharma Inc’s shares are in the hands of company insiders while institutional holders own 35.11% of the company’s shares. Also important is the data on short interest which shows that short shares stood at 0.39 million on 2025-02-28, giving us a short ratio of 0.58. The data shows that as of 2025-02-28 short interest in AEON Biopharma Inc (AEON) stood at 3650.0 of shares outstanding, with shares short rising to 41352.0 registered in 2025-01-31. Current price change has pushed the stock -98.14% YTD, which shows the potential for further growth is there. It is this reason that could see investor optimism for the AEON stock continues to rise going into the next quarter.
